bca101,pembrolizumab,cetuximab
bicara,merck,eli lilly
['bca101', 'bca101 ', 'pembro', 'hanna']
encouraging anti-tumor activity for patients w/metastatic head &amp; neck squamous cell carcinoma who are hpv-negative and treated with bifunctional egfr/tgf inhibitor bca101 w/pembrolizumab. dose expansion results reported by 's glenn hanna, md, ( ) at #asco23. 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090